•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Advisors Capital Management LLC increased its holdings in Abbott Laboratories (NYSE: ABT) by 3.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund held 209,652 shares after purchasing an additional 6,743 shares during the quarter, and its stake was valued at $26,267,000 at the end of the reporting period.
Other hedge funds and institutional investors also reported changes in their positions in Abbott Laboratories. Harbor Capital Advisors Inc. purchased a new stake in the fourth quarter worth approximately $27,000. Cloud Capital Management LLC, Guerra Advisors Inc, Bridge Generations Wealth Management LLC, and Copia Wealth Management each purchased new stakes in the third quarter, with values of approximately $29,000, $31,000, $33,000, and $38,000, respectively.
Overall, 75.18% of the stock is currently owned by hedge funds and other institutional investors.
Abbott Laboratories shares opened at $91.16 on Friday. The stock’s 50-day moving average price is $105.96, while its 200-day moving average price is $117.23. The company has a 1-year low of $90.72 and a 1-year high of $139.06.
Abbott Laboratories has a market capitalization of $158.76 billion. Valuation and risk metrics include a P/E ratio of 25.53, a P/E/G ratio of 1.54, and a beta of 0.79. The company’s balance-sheet ratios include a debt-to-equity ratio of 0.19, a current ratio of 1.58, and a quick ratio of 1.18.
Abbott Laboratories last reported quarterly earnings on Thursday, April 16. The company posted earnings of $1.15 per share for the quarter, slightly above analysts’ consensus estimate of $1.14 by $0.01. Abbott Laboratories reported return on equity of 17.71% and a net margin of 13.90%.
Revenue for the quarter was $11.16 billion, compared with analyst estimates of $10.99 billion. In the prior-year quarter, Abbott reported $1.09 earnings per share. Quarterly revenue increased 7.8% year over year.
For forward guidance, Abbott Laboratories set FY 2026 guidance at 5.38–5.58 EPS and Q2 2026 guidance at 1.25–1.31 EPS. Sell-side analysts forecast Abbott will post 5.48 EPS for the current fiscal year.
Abbott Laboratories also disclosed a quarterly dividend payable on Friday, May 15. Investors of record on Wednesday, April 15 will receive $0.63 per share. The dividend equates to $2.52 on an annualized basis and implies a yield of 2.8%. The ex-dividend date is Wednesday, April 15. The company’s dividend payout ratio is 70.59%.
Insider activity reported for Abbott Laboratories included sales by executives. EVP Daniel Gesua Sive Salvadori sold 885 shares on Monday, March 2 at an average price of $115.58, for a total transaction value of $102,288.30. After the sale, the executive vice president directly owned 146,377 shares, valued at approximately $16,918,253.66.
EVP Mary K. Moreland sold 613 shares on Monday, March 2 at an average price of $115.58, for a total value of $70,850.54. Following the sale, she owned 104,291 shares, valued at approximately $12,053,953.78.
Insiders sold 3,055 shares of company stock valued at $353,097 in the last 90 days. Corporate insiders own 0.46% of the stock.
Several research firms commented on Abbott Laboratories. Weiss Ratings lowered the company from a hold (c) rating to a hold (c-) rating. Stifel Nicolaus cut its price target from $145.00 to $120.00 and maintained a buy rating. Mizuho reduced its price target from $125.00 to $115.00 and set a neutral rating. Royal Bank of Canada lowered its price target from $135.00 to $130.00 and kept an outperform rating. JPMorgan Chase & Co. reduced its price target from $123.00 to $110.00 and set an overweight rating.
In total, two analysts rate the stock as Strong Buy, nineteen rate it as Buy, and five rate it as Hold. MarketBeat data indicates a consensus rating of Moderate Buy and a consensus target price of $119.43.
Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois. Founded in 1888, it operates through business areas focused on diagnostics, medical devices, nutritionals, and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers, and direct-to-consumer channels with products intended to diagnose, treat, and manage a range of health conditions.
In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions, and biomarkers, including its Alinity family of instruments and rapid-test solutions.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
